Important Interactions of Immunosuppressants With Experimental Therapies for Novel Coronavirus Disease (COVID-19): How to Act

Ther Drug Monit. 2020 Aug;42(4):652-653. doi: 10.1097/FTD.0000000000000766.

Authors

Tanja R Zijp¹, Martha L Toren-Wielema¹, Prashant V Nannan Panday¹, Jos G W Kosterink¹, Stefan P Berger^{2

3}, Daan J Touw¹

Affiliations

¹ Department of Clinical Pharmacy and Pharmacology, University Medical Center Groningen and University of Groningen, Groningen, the Netherlands.
² Department of Internal Medicine, Division of Nephrology, University Medical Center Groningen and University of Groningen, Groningen, the Netherlands.
³ UMC Groningen Comprehensive Transplant Center, University Medical Center Groningen and University of Groningen, Groningen, the Netherlands.

PMID: 32433189
DOI: 10.1097/FTD.0000000000000766

No abstract available

Publication types

Letter
Comment

MeSH terms

Adult
Betacoronavirus
COVID-19
COVID-19 Drug Treatment
Coronavirus Infections* / drug therapy
Coronavirus*
Humans
Immunosuppressive Agents
Lopinavir
Pandemics*
Pneumonia, Viral*
Ritonavir
SARS-CoV-2
Therapies, Investigational

Substances

Immunosuppressive Agents
Lopinavir
Ritonavir